



OPEN ACCESS

EDITED AND REVIEWED BY
Niccolo Terrando,
Duke University, United States

*CORRESPONDENCE

Jianmin Chen

✉ jianmin.chen@qmul.ac.uk

Christoph Thiernemann

✉ c.thiernemann@qmul.ac.uk

RECEIVED 03 July 2025

ACCEPTED 18 July 2025

PUBLISHED 31 July 2025

CITATION

Chen J, Purvis GSD, Collotta D, Al Zoubi S, Sugimoto MA, Cacace A, Martin L, Colas RA, Collino M, Dalli J and Thiernemann C (2025) Correction: RvE1 attenuates polymicrobial sepsis-induced cardiac dysfunction and enhances bacterial clearance. *Front. Immunol.* 16:1659224. doi: 10.3389/fimmu.2025.1659224

COPYRIGHT

© 2025 Chen, Purvis, Collotta, Al Zoubi, Sugimoto, Cacace, Martin, Colas, Collino, Dalli and Thiernemann. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correction: RvE1 attenuates polymicrobial sepsis-induced cardiac dysfunction and enhances bacterial clearance

Jianmin Chen^{1*}, Gareth S. D. Purvis², Debora Collotta³, Sura Al Zoubi^{1,4}, Michelle A. Sugimoto¹, Antonino Cacace^{1,5}, Lukas Martin^{1,6}, Roman A. Colas¹, Massimo Collino³, Jesmond Dalli¹ and Christoph Thiernemann^{1*}

¹Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ²Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom, ³Department of Drug Science and Technology, University of Turin, Turin, Italy, ⁴Department of Basic Medical Sciences, School of Medicine, Al-Balqa Applied University, As-Salt, Jordan, ⁵Diabetes Complication Research Centre, School of Medicine, UCD Conway Institute, University College Dublin, Dublin, Ireland, ⁶Department of Intensive Care and Intermediate Care, RWTH University Hospital Aachen, Aachen, Germany

KEYWORDS

polymicrobial sepsis, resolvin E1, bacterial clearance, immune response, cardiomyopathy

A Correction on

RvE1 attenuates polymicrobial sepsis-induced cardiac dysfunction and enhances bacterial clearance

By Chen J, Purvis GSD, Collotta D, Al Zoubi S, Sugimoto MA, Cacace A, Martin L, Colas RA, Collino M, Dalli J and Thiernemann C (2020). *Front. Immunol.* 11:2080. doi: 10.3389/fimmu.2020.02080

There was a mistake in **Figure 3A** as published. The previous image of **Figure 3A** (MHCII vs. SSC-A scatter plot) was selected from a mouse in the 24-hour post-CLP group that had received RvE1 treatment, as we initially understood that RvE1-treated mice were also subjected to 24-hour CLP. However, to avoid any further confusion, we have now replaced this scatter plot with an image from a mouse subjected to CLP without RvE1 treatment. This change more accurately reflects the legend of **Figure 3A**: “(A) Flow cytometry gating strategy of mouse peritoneal immune cells 24 h post-CLP”. The corrected **Figure 3** and its caption appear below.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.




FIGURE 3

RvE1 treatment enhances MHC II⁻ macrophage recruitment in peritoneal cavity. Mice underwent CLP surgery. One hour after CLP, mice were treated with either RvE1 (1 μg/mouse *i.v.*) or vehicle (100 μl PBS, 0.1% Ethanol). (A) Flow cytometry gating strategy of mouse peritoneal immune cells 24 h post-CLP. (B) Scattergrams illustrating monocyte/macrophage (identified as Ly6G⁺CD64⁺) and neutrophil (identified as Ly6G⁺CD64⁻) positive events in peritoneal lavages from CLP mice with vehicle or RvE1 treatment. (C, D) Cumulative data for peritoneal CD64⁺ monocytes/macrophages and Ly6G⁺ neutrophils. (E) Scattergrams illustrating macrophage (identified as CD64^{high}Ly6C^{low}) and monocyte (identified as CD64^{low}Ly6C^{high}) positive events in peritoneal lavages from CLP mice with vehicle or RvE1 treatment. (F, G) Cumulative data for peritoneal CD64^{high}Ly6C^{low} macrophages and CD64^{low}Ly6C^{high} monocytes. (H) Scattergrams illustrating MHC II⁻ macrophage and MHC II⁺ macrophage positive events in peritoneal lavages from CLP mice with vehicle or RvE1 treatment. (I, J) Cumulative data for peritoneal MHC II⁻ macrophages and MHC II⁺ macrophages. Data are expressed as mean ± SEM of four mice for vehicle group and five mice for RvE1 treatment group. Data were analyzed by unpaired Student's t-test. **P* < 0.05 versus CLP + Vehicle group.